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for intervention and treatment, and also production loss of
patients as indirect costs. RESULTS: A total of 185 question-
naires on SF-36 and EQ-5D were returned (88 stepped, 97 ordi-
nary). There was no statistically signiﬁcant difference between
the scores of two groups. The expected costs a patient in the deci-
sion model were estimated as US$4072 (US$ = JPY110) for the
stepped care, and US$2695 for the ordinary care with the dis-
count of 3% a year in three years. The incremental cost-
effectiveness ratio was US$17,636 in terms of cost per patient
prevented from becoming Type-2 diabetes. CONCLUSIONS:
The analysis on the JDPP intermediate report suggested that the
stepped care resulted in increased costs for prevention compar-
ing to the ordinary care in three years, maintaining the same level
of QOLs in both groups.
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OBJECTIVES: Pioglitazone (PIO), a PPARã-Agonist has been
approved in Germany for treatment of patients with Type-2-
diabetes in mono-and combination therapy with either meformin
(MET) or sulfonylurea. Long-term studies with a treatment
period of 104 weeks involving 1197 patients comparing PIO
with Gliclazide (GLIC) have recently been published. These
studies revealed a superior effect of PIO in sustaining the HbA1C
reduction compared to GLIC. Whether this translates to beneﬁts
with regard to cost-effectiveness is currently unknown.
METHODS: This study compared the clinical effects and costs
of PIO (15–45mg) combination therapy (MET) and 30–45mg
monotherapy with GLIC + MET or GLIC monotherapy, respec-
tively. The validated IMIB Markov diabetes model was adapted.
The mean time transferring a patient to insulin therapy (MIT),
life expectancy (LE and ÄLE), the related NNT to avoid 1
event/1 death and the incremental cost-effectiveness as cost per
life year gained (C/LYG) discounted at 0% and 5% were calcu-
lated. RESULTS: In monotherapy PIO was associated with a
higher MIT 11.70 vs. 11.39 years and a LE of 15.90 vs. 15.45
years (ÄLE: 0.44 years) vs. GLIC. For PIO vs. GLIC the NNT
to avoid 1 event and 1 death were 32 and 54, respectively. When
leaving the C/LYG undiscounted, PIO dominated GLIC and
amounted to 2997€ (5%) vs. GLIC. In combination therapy PIO
+ MET was associated with a higher MIT 9.73 vs. 9.23 years
and a LE of 15.58 vs. 14.94 years (ÄLE: 0.64 years) compared
to GLIC + MET. For PIO + MET vs. GLIC + MET the NNT to
avoid 1 event and 1 death were 28 and 36, respectively. The
C/LYG for PIO + MET was calculated with 1445€ (0%) and
5480€ (5%) vs. GLIC + MET. CONCLUSIONS: The study indi-
cates that PIO in mono, as well as in combination therapy, is
preferable in terms of health outcomes and cost-effectiveness
compared to GLIC in patients with Type-2-diabetes.
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OBJECTIVES: Glucophage®XR is a new extended-release for-
mulation of metformin which permits once-daily medication.
Clinical studies show that Glucophage®XR demonstrate the
same antihyperglycemic efﬁcacy as immediate-release metformin
(Glucophage®). However, in a retrospective chart review,
patients with type 2 diabetes experienced fewer GI side effects
and comparable or better glycemic control, based on HbA1C
measurement, when switched from Glucophage® to Glu-
cophage®XR. Mean HbA1c values were 7.8%-points before the
switch and 7.5%-points afterwards. The CORE Diabetes Model,
a peer-reviewed, validated, model was used to project the long-
term cost-effectiveness of switching patients from Glucophage®
to Glucophage®XR. METHODS: The CORE Diabetes model
employs standard Markov/Monte Carlo simulation techniques
to describe the long-term incidence and progression of diabetes-
related complications. Transition probabilities were derived from
major diabetes studies. Clinical effects of switching from Glu-
cophage® to Glucophage®XR were derived from a retrospec-
tive database study. The analysis was performed using published
UK-speciﬁc costs, health care resource utilization, clinical data
and recommended discount rates of 3.5% for costs and clinical
outcomes. A lifetime horizon and NHS payer perspective was
taken. Only direct costs were considered. Sensitivity analyses
were performed. RESULTS: Switching patients from Glu-
cophage® to Glucophage®XR was projected to improve life
expectancy by 0.10 years, quality-adjusted life expectancy by
0.09 years, and decrease overall lifetime costs by £201/patient.
Results were most sensitive to variations in assumptions about
changes in HbA1c when patients are switched from Glu-
cophage® to Glucophage®XR, and the relative costs of treat-
ment. CONCLUSIONS: In real life, due to improved tolerability,
compliance, and glycemic control, switching patients from Glu-
cophage® to Glucophage®XR may improve longterm patient
outcomes and lead to overall cost savings.
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OBJECTIVES: In the province of Styria, Austria, a structured
patient education program for patients with type-2 diabetes was
established in the year 2000. In this open label, prospective
cohort study (n = 1150) follow-up data after one year have been
analysed to document the potential effects over 10 years using
the CORE-Diabetes Model, a validated, peer reviewed simula-
tion model. Patients outcomes and total costs were calculated.
METHODS: A Styria-wide patient education program for type-
2 diabetes was established for general practitioners to improve
treatment outcomes in diabetes care. The program is funded by
the public health care system and a standardised documentation
at baseline and after one year was used. Intermediate results after
one year were incorporated in the CORE diabetes model and
linked with Austria speciﬁc cost data. Monte-Carlo-Simulation
(n = 5.000) over ten years projected long term effects of single
patient education. A virtual control group was assumed to be
treated like general Styrian diabetic population. Discount rate
was 5 % annually. RESULTS: The average life expectancy
increased by 0.29 years (7.32 ± 3.48 vs. 7.03 ± 3.5) under edu-
cation, the total costs over ten years decreased by 774€ per
patient (20,496€ ± 30,335€ vs. 21,270€ ± 37,917€) or 3.8%.
Patient education leads to improved foot care and retinal screen-
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ing as well as renal therapy but to higher general treatment costs
(educated: 4364€; not educated: 2795€). Total number of long
term events prevented for 5.000 patients was 1.810. Results were
most sensitive to improvements in screening rates and the costs
of implementing the program. CONCLUSIONS: Patient educa-
tion reduced late complications and therefore is able to com-
pensate for higher management and treatment costs. Results of
model-based projections demonstrated that the program may be
cost-saving over ten years in an Austrian cost setting.
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OBJECTIVES: The therapy-switching threshold is the blood
glucose level at which a treatment is failing to maintain gly-
caemic control. We assess the impact of a change in therapy-
switching threshold on lifetime cost-effectiveness of treatment
for Type-2 Diabetes in Germany. METHODS: DiDACT is an
established model of Type-2 diabetes, which includes all relevant
costs in taking a sickness funds perspective. German guidelines
recommend a therapy-switching threshold of HbA1c < 7.0%. We
assess an increase to 7.5%, because some patients cannot achieve
a lower threshold in clinical practice. We simulated treatment
histories for cohorts of 1000 obese patients (mean BMI = 34).
Following Metformin monotherapy failure, combination therapy
adding Rosiglitazone (8mg/d) was compared to adding Gliben-
clamide. Costs were discounted at 5% pa. We present both
within-group “absolute” and between-group “incremental”
comparisons. RESULTS: A higher therapy-switching threshold
simultaneously leads to inferior glycaemic control and extended
oral anti-diabetic viability. Deteriorating glycaemic control
increases morbidity and mortality. The absolute effect of weaker
control is smaller in the Rosiglitazone cohort (104 fewer Life-
Years compared to 185 with Glibenclamide). Extending oral
therapy before requiring insulin improves quality-of-life (QOL).
The absolute effect of weaker control is smaller in the Rosigli-
tazone cohort (115 more QALYs compared to 266 with Gliben-
clamide). Superior glycaemic control in the Rosiglitazone cohort
yields incremental Life-Years/QALYs of 188/295 (HbA1c 7.0%)
and 270/143 (HbA1c 7.5%). The higher threshold leads to cost
increases in both cohorts, but reduces incremental costs. The
higher threshold reduces the discounted incremental cost-
effectiveness ratio (ICER) per Life-Year from 27,516€ to 18,345€
and increases the ICER per QALY from 17,523€ to 34,471€.
CONCLUSIONS: When selecting the therapy-switching thresh-
old there is a trade-off between glycaemic control and QOL.
ICERs for proposed care adding Rosiglitazone to Metformin
remain robust to changes in therapy-switching threshold. It is
important to consider both absolute and incremental effects
when changing key model parameters.
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OBJECTIVES: The aim of the study was to assess the costs of
early detection of DM in the Polish population. METHODS: An
analysis of the costs of diagnosis of DM in primary care was
based on an epidemiological study “Screen-Pol 2”, which was
performed in 2003 and 2004, in 119 centres situated through-
out Poland. The detection of DM was carried out according to
ADA and WHO criteria. During the diagnostic process the fol-
lowing tests were performed: random blood capillary glucose
(RBCG), fasting venous plasma concentration (FPG) and oral
glucose tolerance (OGTT). The tests constituted sequential 
steps in a diagnostic pathway used in primary care in Poland.
Third party payer perspective was applied. RESULTS: A total 
of 11,418 undiagnosed patients took part in the study. The
average cost of detection of DM was 23.22€*. The cost of detec-
tion of one case of DM only by RBCG was 20.62€. The cost 
of detection of DM with FPG was 29.43€ and 171.15€ (if
repeated). When OGTT was used the cost of each case of DM
detected reached 390.93€. CONCLUSIONS: The early detection
of DM is a simple and cheap procedure, when introduced as a
screening programme. It is 23 times less expensive than one
year’s treatment of a single case of DM in terms of direct medical
costs and 64 times cheaper in terms of indirect costs. (* 1 Euro
= 4.6 PLN).
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OBJECTIVES: This study was undertaken to quantify the cost
of hospitalization for cardiovascular disease (CVD) in patients
with diabetes over a 5-year period. METHODS: The cohort of
patients with diabetes was identiﬁed in the 1996 Massachusetts
inpatient database using ICD-9 codes and unique patient identi-
ﬁers. Index admission was deﬁned as the ﬁrst admission in 1996
where a diagnosis of diabetes was recorded. Readmissions over
the subsequent 5 years (1996–2000) for ischemic heart (IHD)
disease, cerebrovascular disease, congestive heart failure (CHF)
and other CVD were tallied for each patient. Massachusetts hos-
pital costs, including all accommodations and ancillary services
were estimated from the all payer discharge databases adjusted
to national values, for medical inﬂation, by cost-to-charge ratios,
and are reported in 2002 US dollars. RESULTS: Of the 52,859
patients with diabetes identiﬁed in 1996, one third was admit-
ted for CVD at index, mean age was 68 years and 47% were
male. Case fatality rate during the index admission was 4%. Sub-
sequently, 21,778 (44%) of index admission survivors had at
least one readmission (mean: 2.5, range: 1–33) for a CVD
problem within ﬁve years (57% readmission rate for those
admitted for CVD at index). IHD accounted for 31% of CVD-
related readmissions (mean cost per stay: $12,500), cerebrovas-
cular events for 11% (mean: $8100), CHF for 33% (mean:
$8000) and 25% other CVD (mean: $11,100). Total cumulative
cost for all CVD-related admissions over 5 years was roughly
$670 million. CONCLUSIONS: A substantial proportion of 
hospitalized patients with diabetes can be expected to require
additional hospital-level care for CVD within a 5-year period.
Although the total hospital cost for CVD-related events reported
here is impressive, it is conservative, as it captures only one
aspect of care for CVD in these patients. These results empha-
size the profound economic consequences of cardiovascular com-
plications in patients with diabetes.
